In 2 of these patients, who both had a diagnosis of a high-grade glioma and germline TP53 pathogenic variant, the CPS was not identified by the phenotype-first approach, but rather detected by performing WES as part of a precision medicine program or tumor diagnostic work-up. The gene discussed is TP53; the disease is glioma.